Search miRCancer Database

Search by miRNA name:      Or     And       cancer name:        

Example: mir-145, hsa-mir-21, let-7			 Example: breast cancer, lung

Search result for miRNA = 'hsa-mir-23a' Or cancer = '' Total: 29 relations found.

mirId Family/Cluster Cancer Profile PubMed Article
hsa-mir-23a bladder cancer up Micro-RNA profiling in kidney and bladder cancers.
hsa-mir-23a breast cancer up c-MYC regulated miR-23a~24-2~27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2.
hsa-mir-23a breast cancer up MiR-23a promotes TGF-?1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/?-catenin signaling.
hsa-mir-23a colon carcinoma up [Expression and clinical significance of miR-23a and metastasis suppressor 1 in colon carcinoma].
hsa-mir-23a colorectal cancer up Circulating Exosomal microRNAs as Biomarkers of Colon Cancer.
hsa-mir-23a colorectal cancer up MicroRNA-23a promotes colorectal cancer cell survival by targeting PDK4.
hsa-mir-23a gastric adenocarcinoma up MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor.
hsa-mir-23a gastric adenocarcinoma up miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells.
hsa-mir-23a gastric cancer up miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3.
hsa-mir-23a gastric cancer up MiR-23a in Amplified 19p13.13 Loci Targets Metallothionein 2A and Promotes Growth in Gastric Cancer Cells.
hsa-mir-23a gastric cancer up Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer.
hsa-mir-23a gastric cancer up miR-23a/b promote tumor growth and suppress apoptosis by targeting PDCD4 in gastric cancer.
hsa-mir-23a gastric cancer up microRNA-23a promotes cell growth and metastasis in gastric cancer via targeting SPRY2-mediated ERK signaling.
hsa-mir-23a glioma up Targeting microRNA-23a to inhibit glioma cell invasion via HOXD10.
hsa-mir-23a glioma up Identification of microRNAs associated with glioma diagnosis and prognosis.
hsa-mir-23a hepatocellular carcinoma up Stat3-mediated activation of miR-23a suppresses gluconeogenesis in hepatocellular carcinoma by downregulating G6PC and PGC-1?
hsa-mir-23a hepatocellular carcinoma up MicroRNA-23a downregulates the expression of interferon regulatory factor-1 in hepatocellular carcinoma cells.
hsa-mir-23a hepatocellular carcinoma up MicroRNAs and clinical implications in hepatocellular carcinoma.
hsa-mir-23a laryngeal cancer up High microRNA-23a expression in laryngeal squamous cell carcinoma is associated with poor patient prognosis.
hsa-mir-23a laryngeal carcinoma up Upregulation of microRNA-23a regulates proliferation and apoptosis by targeting APAF-1 in laryngeal carcinoma.
hsa-mir-23a malignant melanoma down MicroRNA-23a inhibits melanoma cell proliferation, migration, and invasion in mice through a negative feedback regulation of sdcbp and the MAPK/ERK signaling pathway.
hsa-mir-23a neuroblastoma up MicroRNA-23a promotes neuroblastoma cell metastasis by targeting CDH1.
hsa-mir-23a non-small cell lung cancer up Clinical value of microRNA-23a upregulation in non-small cell lung cancer.
hsa-mir-23a osteosarcoma down MiR-23a Functions as a Tumor Suppressor in Osteosarcoma.
hsa-mir-23a osteosarcoma down miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1.
hsa-mir-23a pancreatic cancer up MicroRNA-23a promotes pancreatic cancer metastasis by targeting epithelial splicing regulator protein 1.
hsa-mir-23a prostate cancer down Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway.
hsa-mir-23a-3p acute myeloid leukemia up Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia.
hsa-mir-23a-3p renal cell carcinoma up MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC.